| Blood and blood-forming organs | |||||
|---|---|---|---|---|---|
| Blood and blood-forming organs / Hypoplastic, haemolytic, and renal anaemias | |||||
| darbepoetin alfa | Hospital only |
NICE TA323 |
|||
| Solution for injection | |||||
| Aranesp (Amgen Ltd) | Hospital only | ||||
| Aranesp SureClick (Amgen Ltd) | Hospital only | ||||
| eltrombopag | Hospital only |
NICE TA293 |
|||
| Oral tablet | |||||
| Eltrombopag (Non-proprietary) | |||||
| Revolade (Novartis Pharmaceuticals UK Ltd) | |||||
| Powder for oral suspension | |||||
| Revolade (Novartis Pharmaceuticals UK Ltd) | |||||
| epoetin alfa | Hospital only |
NICE TA323 |
|||
| Solution for injection | |||||
| Eprex (Janssen-Cilag Ltd) | Hospital only | ||||
| epoetin beta | Hospital only |
NICE TA323 |
|||
| Solution for injection | |||||
| NeoRecormon (Roche Products Ltd) | Hospital only | ||||
| epoetin zeta | Hospital only |
NICE TA323 |
|||
| Solution for injection | |||||
| Retacrit (Pfizer Ltd) | Hospital only | ||||
| methoxy polyethylene glycol-epoetin beta | Hospital only | ||||
| Solution for injection | |||||
| Mircera (Roche Products Ltd) | Hospital only | ||||
| oxymetholone | Hospital only | ||||
| Oral capsule | |||||
| Oxymetholone (Non-proprietary) | |||||
| roxadustat | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA807 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Oral tablet | |||||
| Evrenzo (Astellas Pharma Ltd) | |||||
| Blood and blood-forming organs / Sickle-cell disease | |||||
| VOXELOTOR | Hospital only | ||||
| crizanlizumab | Hospital only |
NICE TA743 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s). |
|||||
| hydroxycarbamide | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral solution | |||||
| Xromi (Nova Laboratories Ltd) | |||||
| Oral tablet | |||||
| Siklos (Masters Pharmaceuticals Ltd) | |||||
| Oral capsule | |||||
| Hydroxycarbamide (Non-proprietary) | |||||
| Droxia (Imported (United States)) | |||||
| Hydrea (Neon Healthcare Ltd) | |||||
| voxelotor |
NICE TA981 |
||||
| Oral tablet | |||||
| Oxbryta (Pfizer Ltd) | |||||
| Blood and blood-forming organs / Atypical haemolytic uraemic syndrome and paroxysmal nocturnal haemoglobinuria | |||||
| eculizumab | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE HST1 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
|
Where negative or terminated NICE Technology Appraisal(s) apply to this medicine
This medicine is not recommended for use for the indication(s) specified in the relevant NICE Technology Appraisal(s) as currently NICE cannot recommend its use. |
|||||
| Solution for infusion | |||||
| Bekemv (Amgen Ltd) | |||||
| Epysqli (Samsung Bioepis NL B.V. Ltd) | |||||
| Soliris (Alexion Pharma UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| pegcetacoplan | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA778 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Solution for infusion | |||||
| Aspaveli (Swedish Orphan Biovitrum Ltd) | |||||
| ravulizumab | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA698 NICE TA710 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Solution for infusion | |||||
| Ultomiris (Alexion Pharma UK Ltd) | |||||
| Blood and blood-forming organs / Iron deficiency anaemia | |||||
| ferric carboxymaltose | Hospital only | ||||
|
Ferinject® (ferric carboxymaltose) reserved for those with high risk of developing hypersensitivity reactions
May 2022 - the Joint Prescribing Group (JPG) recommended for Ferinject® to be reserved for those with high risk of developing hypersensitivity reactions. Monofer® (ferric derisomaltose) would be the first choice parenteral iron for the treatment of iron deficiency at Homerton hospital. |
|||||
| Solution for injection | |||||
| Ferinject (Vifor Pharma UK Ltd) | Hospital only | ||||
|
Ferinject® (ferric carboxymaltose) reserved for those with high risk of developing hypersensitivity reactions
May 2022 - the Joint Prescribing Group (JPG) recommended for Ferinject® to be reserved for those with high risk of developing hypersensitivity reactions. Monofer® (ferric derisomaltose) would be the first choice parenteral iron for the treatment of iron deficiency at Homerton hospital. |
|||||
| ferric derisomaltose | Hospital only | ||||
|
Monofer® (ferric derisomaltose) for the treatment of iron deficiency anaemia
May 2022 - The Joint Prescribing Group (JPG) agreed to approve the addition of Monofer® as first line parenteral iron for the treatment of iron deficiency at Homerton. Formulary status: Blue (hospital only) |
|||||
| Solution for injection | |||||
| Ferric derisomaltose (Non-proprietary) | |||||
| Diafer (Pharmacosmos UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| ferric maltol | Not approved for prescribing | ||||
| Oral capsule | |||||
| Feraccru (Norgine Pharmaceuticals Ltd) | |||||
| ferrous fumarate | Joint formulary choice | ||||
| Oral solution | |||||
| Ferrous fumarate (Non-proprietary) | Joint formulary choice | ||||
| AacuFer (TriOn Pharma Ltd) | |||||
| AadFer (Essential-Healthcare Ltd) | |||||
| FerroEss (Essential-Healthcare Ltd) | |||||
| Galfer (Thornton & Ross Ltd) | Joint formulary choice | ||||
| Oral tablet | |||||
| Ferrous fumarate (Non-proprietary) | |||||
| FerroDose-F (TriOn Pharma Ltd) | |||||
| FerroEss (Essential-Healthcare Ltd) | |||||
| Oral capsule | |||||
| Ferrous fumarate (Non-proprietary) | |||||
| FerroDose-F (TriOn Pharma Ltd) | |||||
| FerroEss (Essential-Healthcare Ltd) | |||||
| Galfer (Thornton & Ross Ltd) | |||||
| ferrous fumarate with folic acid | Not approved for prescribing | ||||
| ferrous gluconate | Not approved for prescribing | ||||
| Oral tablet | |||||
| Ferrous gluconate (Non-proprietary) | |||||
| AadFer (Essential-Healthcare Ltd) | |||||
| FerroDose-G (TriOn Pharma Ltd) | |||||
| ferrous sulfate | Joint formulary choice | ||||
|
Only ferrous sulfate immediate release tablets are approved for prescribing
Please note ferrous sulfate modified release capsules, modified release tablets and oral drops are not approved for prescribed (non-formulary) |
|||||
| Modified-release tablet | |||||
| Ferrograd (Teofarma S.r.l.) | Not approved for prescribing | ||||
| Oral drops | |||||
| Ferrous sulfate (Non-proprietary) | Not approved for prescribing | ||||
| FerroNorm (Essential-Healthcare Ltd) | |||||
| Oral tablet | |||||
| Ferrous sulfate (Non-proprietary) | |||||
| FerroDose-S (TriOn Pharma Ltd) | |||||
| FerroTab (Essential-Healthcare Ltd) | |||||
| ferrous sulfate with ascorbic acid | Not approved for prescribing | ||||
| Modified-release tablet | |||||
| Ferrograd C (Teofarma S.r.l.) | Not approved for prescribing | ||||
| ferrous sulfate with folic acid | Not approved for prescribing | ||||
| Modified-release tablet | |||||
| Ferrograd Folic (Teofarma S.r.l.) | Not approved for prescribing | ||||
| iron dextran | Hospital only | ||||
| Solution for injection | |||||
| CosmoFer (Pharmacosmos UK Ltd) | Hospital only | ||||
| iron sucrose | Hospital only | ||||
| Solution for injection | |||||
| Venofer (Imported (United States), Vifor Pharma UK Ltd) | Hospital only | ||||
| sodium feredetate | Joint formulary choice | ||||
| Oral solution | |||||
| Sodium feredetate (Non-proprietary) | Joint formulary choice | ||||
| Sytron (Kyowa Kirin International UK NewCo Ltd) | Joint formulary choice | ||||
| Blood and blood-forming organs / Megaloblastic anaemia | |||||
| cyanocobalamin | Not approved for prescribing | ||||
| Oral tablet | |||||
| Cyanocobalamin (Non-proprietary) | |||||
| CyanocoB12 (TriOn Pharma Ltd) | |||||
| CyanocoMinn (Essential-Healthcare Ltd) | |||||
| Orobalin (Northumbria Pharma Ltd) | |||||
| SunVit-Pro (SunVit-D3 Ltd) | |||||
| folic acid | Joint formulary choice | ||||
| Oral solution | |||||
| Folic acid (Non-proprietary) | Joint formulary choice | ||||
| Lexpec (Rosemont Pharmaceuticals Ltd) | Joint formulary choice | ||||
| Oral tablet | |||||
| Folic acid (Non-proprietary) | |||||
| hydroxocobalamin | Joint formulary choice | ||||
| Solution for injection | |||||
| Hydroxocobalamin (Non-proprietary) | Joint formulary choice | ||||
| Cobalin (Advanz Pharma) | Joint formulary choice | ||||
| Neo-Cytamen (RPH Pharmaceuticals AB) | Joint formulary choice | ||||
| Powder for solution for infusion | |||||
| Cyanokit (SERB) | |||||
| Blood and blood-forming organs / Iron overload | |||||
| deferasirox | Hospital only | ||||
| Oral tablet | |||||
| Deferasirox (Non-proprietary) | |||||
| Exjade (Novartis Pharmaceuticals UK Ltd) | |||||
| deferiprone | Hospital only | ||||
| Oral solution | |||||
| Ferriprox (Chiesi Ltd) | Hospital only | ||||
| Oral tablet | |||||
| Deferiprone (Non-proprietary) | |||||
| Ferriprox (Chiesi Ltd) | |||||
| desferrioxamine mesilate | Hospital only | ||||
| Powder for solution for injection | |||||
| Desferrioxamine mesilate (Non-proprietary) | Hospital only | ||||
| Desferal (Novartis Pharmaceuticals UK Ltd) | Hospital only | ||||
| Blood and blood-forming organs / Neutropenia | |||||
| filgrastim | Hospital only | ||||
| Solution for injection | |||||
| Accofil (Accord-UK Ltd) | Hospital only | ||||
| Neupogen (Amgen Ltd) | Hospital only | ||||
| Neupogen Singleject (Amgen Ltd) | Hospital only | ||||
| Nivestim (Pfizer Ltd) | Hospital only | ||||
| Zarzio (Sandoz Ltd) | Hospital only | ||||
| lenograstim | Hospital only | ||||
| Powder and solvent for solution for injection | |||||
| Granocyte (Chugai Pharma UK Ltd) | Hospital only | ||||
| lipegfilgrastim | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Solution for injection | |||||
| Lonquex (Teva UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| pegfilgrastim | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Solution for injection | |||||
| Neulasta (Amgen Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Pelgraz (Accord-UK Ltd) | |||||
| Pelmeg (Napp Pharmaceuticals Ltd) | |||||
| Ziextenzo (Sandoz Ltd) | |||||
| Blood and blood-forming organs / Stem cell mobilisation | |||||
| plerixafor | Not approved for prescribing | ||||
| Solution for injection | |||||
| Plerixafor (Non-proprietary) | |||||
| Mozobil (Sanofi) | Not approved for prescribing | ||||
| Blood and blood-forming organs / Essential thrombocythaemia | |||||
| anagrelide [Specialist drug] | Hospital only | ||||
| Oral capsule | |||||
| Anagrelide (Non-proprietary) | |||||
| Xagrid (Takeda UK Ltd) | |||||
| hydroxycarbamide | Shared care guideline | ||||
|
A formal Shared Care Guideline (SCG) may be available
Happy to prescribe If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. Unhappy to prescribe If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. |
|||||
| Oral solution | |||||
| Xromi (Nova Laboratories Ltd) | |||||
| Oral tablet | |||||
| Siklos (Masters Pharmaceuticals Ltd) | |||||
| Oral capsule | |||||
| Hydroxycarbamide (Non-proprietary) | |||||
| Droxia (Imported (United States)) | |||||
| Hydrea (Neon Healthcare Ltd) | |||||
| Blood and blood-forming organs / Thrombocytopenias | |||||
| avatrombopag | Hospital only |
NICE TA626 NICE TA853 |
|||
|
NICE TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (June 2020)
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
|
NICE TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia (December 2022)
This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the NICE Technology Appraisal. |
|||||
| Oral tablet | |||||
| Doptelet (Swedish Orphan Biovitrum Ltd) | |||||
| lusutrombopag | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA617 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Oral tablet | |||||
| Mulpleo (Shionogi BV) | |||||
| Blood and blood-forming organs / Acquired thrombotic thrombocytopenic purpura | |||||
| caplacizumab | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA667 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Powder and solvent for solution for injection | |||||
| Cablivi (Sanofi) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| Blood and blood-forming organs / Immune thrombocytopenia | |||||
| eltrombopag |
NICE TA293 |
||||
| Oral tablet | |||||
| Eltrombopag (Non-proprietary) | |||||
| Revolade (Novartis Pharmaceuticals UK Ltd) | |||||
| Powder for oral suspension | |||||
| Revolade (Novartis Pharmaceuticals UK Ltd) | |||||
| fostamatinib | Non-formulary at HHFT and not suitable for primary care prescribing |
NICE TA835 |
|||
|
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service
This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service. |
|||||
| Oral tablet | |||||
| Tavlesse (Grifols UK Ltd) | Non-formulary at HHFT and not suitable for primary care prescribing | ||||
| romiplostim |
NICE TA221 |
||||
| Powder for solution for injection | |||||
| Nplate (Amgen Ltd) | |||||
| Powder and solvent for solution for injection | |||||
| Nplate (Amgen Ltd) | |||||